Skip to Content

Sangui Biotech International Inc SGBI Stock Quote

| Rating as of


Last close prices updated as of May 26, 2023, 2:32 PM EST | USD
  • Last Close < 0.01
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Investment Style Small Growth
  • Day Range < 0.01  –  < 0.01
  • Year Range < 0.01  –  0.02
  • Market Cap 577,230.0655
  • Volume / Avg 2,000.0 /  14,287.5
  • Price / Sales 7.13
  • Price / Book 39.38
  • Forward Div Yield 2.86%
  • Trailing Div Yield

Morningstar‘s Stock Analysis SGBI

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SGBI

Company Profile SGBI

Business Description

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Bleichenbrucke 9
Hamburg, 20354, DEU
Industry Drug Manufacturers - Specialty & Generic

Competitors & Peers SGBI

Morningstar does not cover competitors or peers for this firm.

FAQs for Sangui Biotech International Inc Stock

No. SGBI does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

SGBI’s market cap is 577,230.07.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

SGBI’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

SGBI’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare SGBI’s historical performance against its industry peers and the overall market.